Preview

Tumors of female reproductive system

Advanced search

First report of observation trial about impact of bisphosphonate`s treatment to the quality of life breast cancer patient with bone metastases

https://doi.org/10.17650/1994-4098-2012-0-2-82-88

Abstract

Increasing survival of oncology patients depends on early diagnostics, developing the new technologies of the treatment and the new drugs. It allows finding out more and more patients with bone metastases. So the answers to the questions about bisphosphonate`s duration, complication of the treatment and improvement of quality of life are very necessary and important. We`ve analyzed long-term (1 year ) introduction of zoledronic acid 4 mg monthly in patients with breast cancer and bone metastasis. The data suggests that long-term treatment of zoledronic acid allows improving quality of life of this kind of patients.

About the Authors

O. V. Zelenova
Central Research Institute for Organization and Informatization of Health Care, Russian Ministry of Health
Russian Federation


L. V. Bolotina
P.A. Herzen Moscow Oncology Research Institute
Russian Federation


L. Yu. Nikitina
Orenburg Regional Clinical Oncology Dispensary
Russian Federation


M. V. Chernikov
AO Aston Consulting, Moscow
Russian Federation


References

1. Coleman R.E. Skeletal complications of malignancy. Cancer 1997;80:1588−94.

2. Lipton A., Theriault R.L., Hortobagyi G.N. et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomised, placebo-controlled trials. Cancer 2000;88:1082−90.

3. Kanis J.A., McCloskey E.V. Bone turnover and biochemical markers in malignancy. Cancer 1997;80(8):1691−5.

4. Fleisch H. Bisphosphonates in bone disease − from the laboratory to the patient. NY: The Parthenon Publishing Group, 1997.

5. Mundy G.R. Preclinical studies of metastases: experimental models and novel techniques to detect micro metastases. Program and abstracts of 22nd San Antonio Breast Cancer Symposium, 1999.

6. Hiraga T., Williams P.J., Ueda A. et al. Zoledronic acid inhibits visceral metastases in the 4T1/ luc mouse breast cancer model. Clin Cancer Res 2004;10:4559−67.

7. Senaratue S.G., Pirianov G., Mansi J.L. et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000;82:1459−68.


Review

For citations:


Zelenova O.V., Bolotina L.V., Nikitina L.Yu., Chernikov M.V. First report of observation trial about impact of bisphosphonate`s treatment to the quality of life breast cancer patient with bone metastases. Tumors of female reproductive system. 2012;(2):82-88. (In Russ.) https://doi.org/10.17650/1994-4098-2012-0-2-82-88

Views: 503


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1994-4098 (Print)
ISSN 1999-8627 (Online)